Lexeo Reports Initial Expression and Biomarker Data of LX1001 in P-I/II Clinical Trial for the Treatment of Alzheimer’s Disease
Shots:
- The low-dose cohort from the P-I/II trial evaluates LX1001 in 15 patients aged ≥50yrs. with AD
- The results showed increases in CSF APOE2 levels from baseline related to CSF APOE4 levels in all evaluated patients with follow-up data @3mos. visit & in 2 patients with follow-up @12mos. visit, reduction in CSF core biomarkers T-tau & P-tau protein levels in 2 patients @12mos. visit. was well-tolerated & no serious AEs were observed
- The company is expected an initial data from the mid-dose cohort & additional 12mos. follow-up data from cohort 1 in H2’22. LX1001 is an AAV-based gene therapy & that deliver the APOE2 gene into the CNS of APOE4 homozygous AD patients to slow disease progression
Ref: Lexeo | Image: Lexeo
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
